2023 World Conference on Lung Cancer (Posters)-EP12.02. Prevalence and Treatment of Advanced NSCLC patients with REarranged During Transfection [RET]-fusion at a South Korean Centre

EP12.02. Prevalence and Treatment of Advanced NSCLC patients with REarranged During Transfection [RET]-fusion at a South Korean Centre - PDF(Slides)

Back to course

Pdf Summary

This document provides an overview of a study conducted at Asan Medical Center in South Korea. The study focused on the prevalence, characteristics, diagnostic methods, treatment patterns, and real-world outcomes of patients with RET fusion-positive advanced non-small cell lung cancer (NSCLC). <br /><br />The study found that RET fusions occur in 4.3% of all patients with NSCLC who underwent next-generation sequencing (NGS) testing. Among patients who received their NGS test as their first biomarker test, the prevalence of RET fusion was 2.6%. The most common fusion partners identified were KIF5B-RET and CCDC6-RET. <br /><br />The study also analyzed the treatment patterns of RET fusion-positive patients. The majority of these patients received systemic anti-cancer therapy (SACT) as their first treatment following NSCLC diagnosis. Among stage IIIB/C patients, a combination of SACT and radiotherapy was commonly used. Checkpoint inhibitors were frequently used in later lines of therapy. <br /><br />The median overall survival (OS) for RET fusion-positive patients was not reached. The survival probabilities at month 36 were 83% for stage IIIB/C patients and 66% for stage IV patients. The median time to treatment discontinuation (TTD) from initiation of the first line of therapy was 7.0 months. The median TTD for stage IIIB/C patients was 5.7 months, while for stage IV patients, it was 7.5 months. <br /><br />The study provides valuable insights into the prevalence and treatment patterns of RET fusion-positive NSCLC in South Korea. These findings contribute to the understanding of this specific subgroup of lung cancer patients and may help guide personalized treatment decisions.

Asset Subtitle

Shinkyo Yoon

Meta Tag

Speaker Shinkyo Yoon

Topic Metastatic NSCLC: Targeted Therapy - FUSIONS

Keywords

study

Asan Medical Center

South Korea

RET fusion-positive

NSCLC

prevalence

treatment patterns

biomarker test

fusion partners

overall survival

personalized treatment decisions